Anixa Biosciences (ANIX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
13 Mar, 2026Opening remarks and agenda
Meeting opened with introductions of board members, executives, legal counsel, and Inspector of Election, emphasizing the virtual format for broader access.
Agenda included formal business (election of directors, executive compensation, auditor ratification), company report, strategy, achievements, 2026 goals, and Q&A session.
Board and executive committee updates
Four directors nominated and elected: Dr. Amit Kumar, Dr. Arnold Baskies, Ms. Emily Gottschalk, and Mr. Lewis Titterton.
Executive compensation approved on a non-binding advisory basis.
Haskell & White LLP ratified as auditors for fiscal year 2026.
Corporate governance
Quorum established with 62% of outstanding shares represented.
Voting conducted virtually, with each share entitled to one vote.
Inspector of Election oversaw voting process and results.
Latest events from Anixa Biosciences
- Innovative cancer therapies and vaccines advance in clinic, supported by strong financials and partnerships.ANIX
Corporate presentation10 Mar 2026 - Advancing first-in-class CAR-T and vaccine therapies for cancer with strong clinical progress.ANIX
Corporate presentation9 Mar 2026 - Net loss narrowed, expenses declined, and clinical programs advanced with strong liquidity.ANIX
Q1 20269 Mar 2026 - Promising cancer therapies advance with strong early data, efficient funding, and key milestones ahead.ANIX
Status Update13 Feb 2026 - Major CAR-T dose escalation approved after strong survival and safety data, setting up a pivotal 2026.ANIX
Fireside chat10 Feb 2026 - Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.ANIX
Proxy Filing28 Jan 2026 - Advancing first-in-class cancer therapies with strong early clinical results and major market potential.ANIX
Investor presentation23 Jan 2026 - Promising early clinical results in cancer therapies, strong financials, and partnership-driven growth.ANIX
2024 Sidoti Virtual Micro-Cap Conference14 Jan 2026 - Net loss narrowed to $11.0M as clinical programs advanced, with $15.2M in year-end liquidity.ANIX
Q4 202512 Jan 2026